SCHEMBL7200645

SCHEMBL7200645

CCN(CC)c1cccc2c(=O)[nH]c3c(c12)Cc1ccccc1-3

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
PARP1 P09874 11/20 0.43
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
GSK3B P49841 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
CCNB3 Q8WWL7 1/20 0.37
AR P10275 1/20 0.36
NTRK1 P04629 1/20 0.36
KDR P35968 1/20 0.36
MAP3K9 P80192 1/20 0.36
MAP3K10 Q02779 1/20 0.36
MAP3K11 Q16584 1/20 0.36
PRNP P04156 2/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833607 0.86 CA1 (0.48) CA1CA2CA4CA6PARP1
SCHEMBL4954076 0.77 CA1 (0.51) CA1CA2CA4CA6PARP1
SCHEMBL9531171 0.76 CA1 (0.40) CA1CA2CA4CA6CCNB2
SCHEMBL2763222 0.74 PARP1 (0.70) CA1CA2CA4CA6PARP1
SCHEMBL4863324 0.73 KMT2A (0.45) CA1CA2CA4CA6PARP1
SCHEMBL16559092 0.72 PNMT (0.49) CA1CA2CA4CA6KDM4E
SCHEMBL2763163 0.71 PARP1 (0.46) CA1CA2CA4CA6PARP1
SCHEMBL6899170 0.70 PARP1 (0.45) CA1CA2CA4CA6PARP1
SCHEMBL10382343 0.69 HIF1A (0.36) CA1CA2CA4CA6KDM4E
SCHEMBL22525079 0.69 ALDH1A1 (0.49) ARKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030096833-A1 Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION 2003-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096833-A1 Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof UGT1A1, XPO1, IPO7 CA1 4597/4885CA2 3994/4885CA4 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.